<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-91323" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Physiology, Muscarinic Receptor</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kudlak</surname>
            <given-names>Megan</given-names>
          </name>
          <aff>American University of the Caribbean School of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Megan Kudlak declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-91323.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Muscarinic receptors are G-coupled protein receptors involved in the parasympathetic nervous system. The only exception to these receptors is the sweat glands, which possess muscarinic receptors but are part of the sympathetic nervous system. They are named due to their increased sensitivity to muscarine, a component found in certain species of mushrooms.<xref ref-type="bibr" rid="article-91323.r1">[1]</xref> The molecule acetylcholine activates muscarinic receptors, allowing for a parasympathetic reaction in any organs and tissues where the receptor is expressed. Nicotinic receptors are ionotropic ligand-gated receptors that are also responsive to Ach, but they are mostly in the central nervous system.<xref ref-type="bibr" rid="article-91323.r2">[2]</xref> Muscarinic receptors are involved in peristalsis, micturition, bronchoconstriction, and several other parasympathetic reactions.<xref ref-type="bibr" rid="article-91323.r3">[3]</xref><xref ref-type="bibr" rid="article-91323.r4">[4]</xref><xref ref-type="bibr" rid="article-91323.r5">[5]</xref>&#x000a0;Muscarinic receptors are a type of ligand-gated G-protein coupled receptor, functioning as either simulative regulative G-proteins (Gs) or inhibitory regulative G-proteins (Gi). &#x000a0;Ach stimulation of Gq to activate PLC and Ca2+. There are five different subtypes of receptors, that when either dysfunctional or overstimulated, can be targeted by several medications allowing for relief of symptoms.</p>
      </sec>
      <sec id="article-91323.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>Acetylcholine is closely associated with muscarinic receptors and activation of the parasympathetic nervous system, except for sweat glands, which are part of the sympathetic response. Overstimulation of these receptors can lead to an increased parasympathetic response leading to harmful effects. Several common diseases can be associated with dysfunctional muscarinic receptors. One major overstimulation of the parasympathetic nervous system is COPD and asthma due to the increased bronchial constriction, which leads to shortness of breath and difficulty breathing. Treatment of COPD involves anticholinergics, whereas asthma treatment uses drugs that cause a reversal of acetylcholine binding or an increase of sympathetic to decrease symptoms.<xref ref-type="bibr" rid="article-91323.r6">[6]</xref></p>
        <p>Muscarinic receptors are prevalent on the detrusor muscle and are involved with contraction. Dysfunction of these receptors leads to overstimulation and increased contraction of the bladder.<xref ref-type="bibr" rid="article-91323.r4">[4]</xref> This disorder characteristically presents as an overactive bladder disease and is treatable with muscarinic antagonists. Several other diseases involving muscarinic receptors are present, such as Parkinson&#x02019;s disease, irritable bowel disorder, and myopia.<xref ref-type="bibr" rid="article-91323.r7">[7]</xref><xref ref-type="bibr" rid="article-91323.r8">[8]</xref><xref ref-type="bibr" rid="article-91323.r9">[9]</xref> Muscarinic antagonistic medications can improve symptoms of the listed disorders by selectively or non-selectively inhibiting the muscarinic receptors. Hyperhidrosis is involved with muscarinic receptors located in the sweat glands that cause them to oversecrete when under sympathetic stimulation.<xref ref-type="bibr" rid="article-91323.r10">[10]</xref></p>
      </sec>
      <sec id="article-91323.s3" sec-type="Cellular Level&#x0000d;&#x0000a;">
        <title>Cellular Level
</title>
        <p>The muscarinic receptor consists of M1, M2, M3, M4, and M5 receptor subtypes. All muscarinic receptors are part of the G-protein coupled receptors (GPCRs). A molecule activates GPCRs; in this case, muscarinic receptors become activated by the neurotransmitter acetylcholine. Activation of GPCRs leads to ligand binding, which leads to the generation of second messengers depending on which class of G protein is present in the receptor.&#x000a0;Gq receptors are excitatory and generate phospholipase C and protein kinase C (PKC). Phospholipase C will then produce second messengers, diacylglycerol (DAG) and inositol triphosphate (IP3). DAG and IP3 work to increase protein kinase and calcium intracellularly, which provide the mechanism for an excitatory reaction. Gi receptors are inhibitory and cause a decrease of adenylyl cyclase, leading to the reduction of protein kinase A. With decreased protein kinase A, cellular levels of cyclic adenosine monophosphate decrease and cause an inhibitory reaction within the cell. M1, M3, M5 are stimulatory receptors and are composed of the Gq protein, whereas M2 and M4 receptors are inhibitory receptors and are composed of the Gi protein.<xref ref-type="bibr" rid="article-91323.r11">[11]</xref></p>
      </sec>
      <sec id="article-91323.s4" sec-type="Organ Systems Involved">
        <title>Organ Systems Involved</title>
        <p>The M1 receptor (Gq) is present in the cerebral cortex, hippocampus, and throughout the brain. The muscarinic receptors in these locations appear to play a role in cognitive functioning.<xref ref-type="bibr" rid="article-91323.r7">[7]</xref>&#x000a0;M2 receptors (Gi) are in the atrium of the heart and the sinoatrial node. M2 receptors, when activated, inhibit sympathetic influence on the heart, reducing contractility and reducing firing from the sinoatrial node, causing an overall decrease in heart rate.<xref ref-type="bibr" rid="article-91323.r12">[12]</xref>&#x000a0;M3 receptors (Gq) are present in smooth muscle structures, such as the bronchi, gastrointestinal tract, pupils, and blood vessels. They are involved in bronchial constriction, gastrointestinal and gallbladder smooth muscle contraction, pupil constriction, and vasodilation of the blood vessels. M3 receptors are also present in sweat glands and are unique in that although they use acetylcholine to activate M3 receptors, they are under sympathetic control.<xref ref-type="bibr" rid="article-91323.r13">[13]</xref><xref ref-type="bibr" rid="article-91323.r14">[14]</xref>&#x000a0;M4 receptors (Gi) are in the CNS. They appear to play a role in dopamine release. M5 receptors (Gq) are located mainly in the substantia nigra of the CNS. These muscarinic receptors are involved in the process of dopamine release.<xref ref-type="bibr" rid="article-91323.r15">[15]</xref></p>
      </sec>
      <sec id="article-91323.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>There are an estimated 358 million patients in the world affected by asthma. Asthma symptoms of dyspnea are secondary to bronchoconstriction and smooth muscle constriction. The increased parasympathetic activity can account for this constriction, including overstimulation of muscarinic receptors by increased release of acetylcholine.<xref ref-type="bibr" rid="article-91323.r16">[16]</xref>&#x000a0;M3 receptors mainly control the contraction of airway smooth muscle. M2 receptors function by inhibiting the action of beta-adrenergic stimulated relaxation.<xref ref-type="bibr" rid="article-91323.r17">[17]</xref>&#x000a0;In asthma, there is an increased level of eosinophils in the airway. Eosinophils release major basic protein, which in turn binds to M2 receptors. Because the M2 receptors are bound, acetylcholine cannot bind to the receptors, and relaxation of the airway becomes difficult; this allows the unbound acetylcholine to bind to M3 receptors, stimulating constriction of the airways thus producing asthma symptoms.<xref ref-type="bibr" rid="article-91323.r16">[16]</xref>&#x000a0;</p>
        <p>Overactive bladder is a syndrome where the detrusor muscle is overactive, causing symptoms of urinary frequency, urgency, and, in some cases, bladder incontinence. There are greater numbers of M2 receptors in the detrusor muscle; however, the smaller population of M3 receptors is most associated with the contraction of the bladder.<xref ref-type="bibr" rid="article-91323.r18">[18]</xref>&#x000a0;M2 indirectly stimulates bladder contraction. When acetylcholine binds to M2 receptors, it&#x000a0;indirectly inhibits beta-adrenoceptors and decreases detrusor relaxation. In cases of overactive bladder, the muscarinic receptors are hypersensitive to acetylcholine and other muscarinic agonists allowing for increased urgency and frequency to urinate due to the increased detrusor contractions.<xref ref-type="bibr" rid="article-91323.r19">[19]</xref>&#x000a0;</p>
        <p>Myopia is more commonly known as nearsightedness, a pervasive disorder with one-third of the United States population affected. Multiple studies have shown that muscarinic receptors, especially the M3 subtype, are involved in developing myopia. Scientists believe that muscarinic receptors are involved in axial elongation, which is present in cases of myopia.<xref ref-type="bibr" rid="article-91323.r20">[20]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-91323.s6" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Either inhibition or stimulation can treat several different diseases and disorders of muscarinic receptors in the affected area. Identifying muscarinic receptors involved in specific pathologies can allow for the development of antagonists and agonists to help decrease symptoms.&#x000a0;In asthma and some COPD cases, a long-acting beta2 agonist (LABA) is used to upregulate sympathetic control in the airways and decrease constriction. Several add-on treatments for asthma have come onto the market throughout the years, and several of these include muscarinic receptor antagonists, also known as long-acting muscarinic antagonists (LAMAs). One of the most recently developed LAMA is tiotropium, which acts on M3 receptors. Tiotropium inhibits smooth muscle cells of the airways and submucosal glands to decrease airway constriction and mucus secretion.<xref ref-type="bibr" rid="article-91323.r21">[21]</xref>&#x000a0;</p>
        <p>Muscarinic antagonists are frequently used in the treatment of overactive bladder. Antagonists work to reduce the spastic contraction of the detrusor muscle.<xref ref-type="bibr" rid="article-91323.r19">[19]</xref>&#x000a0;Oxybutynin is a common treatment due to its anticholinergic properties and the ability to decrease the spastic contraction of the detrusor muscle. Oxybutynin can also be useful in treating hyperhidrosis by blocking muscarinic receptors on eccrine and apocrine sweat glands, reducing their secretion.<xref ref-type="bibr" rid="article-91323.r22">[22]</xref>&#x000a0;Oxybutynin is selective for the M1, M3, and M4 classes of receptors. There are many side effects involving the downregulation of parasympathetic responses, such as dry mouth, blurry vision due to decreased tear production, and constipation.<xref ref-type="bibr" rid="article-91323.r23">[23]</xref>&#x000a0;</p>
        <p>One of the most clinically relevant muscarinic antagonists is atropine. It is an anticholinergic drug that utilizes competitive inhibition to block acetylcholine from binding to muscarinic receptors. In the SA node of the heart, atropine works to block acetylcholine from binding to M2 receptors, which helps downregulate the parasympathetic response and upregulate the sympathetic response in the SA node to increase heart rate and cardiac contractility.<xref ref-type="bibr" rid="article-91323.r24">[24]</xref> Atropine can also be an option to inhibit salivary and mucus glands as well as sweat glands in treating hyperhidrosis. Studies with atropine have shown that it can decrease myopia progression.<xref ref-type="bibr" rid="article-91323.r25">[25]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-91323.s7">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=91323&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=91323">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/91323/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=91323">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-91323.s8">
        <title>References</title>
        <ref id="article-91323.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jin</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Muscarine, imidazole, oxazole and thiazole alkaloids.</article-title>
            <source>Nat Prod Rep</source>
            <year>2016</year>
            <month>Oct</month>
            <day>26</day>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>1268</fpage>
            <page-range>1268-1317</page-range>
            <pub-id pub-id-type="pmid">27714029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gakhar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Vardigan</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>CO</given-names>
              </name>
              <name>
                <surname>Belden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Harvey</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Grishin</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Coles</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Thomson</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Duffy</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Uslaner</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological Characterization of the Novel and Selective <italic>&#x003b1;</italic>7 Nicotinic Acetylcholine Receptor-Positive Allosteric Modulator BNC375.</article-title>
            <source>J Pharmacol Exp Ther</source>
            <year>2020</year>
            <month>May</month>
            <volume>373</volume>
            <issue>2</issue>
            <fpage>311</fpage>
            <page-range>311-324</page-range>
            <pub-id pub-id-type="pmid">32094294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kozlova</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Lotfi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okkema</surname>
                <given-names>PG</given-names>
              </name>
            </person-group>
            <article-title>Cross Talk with the GAR-3 Receptor Contributes to Feeding Defects in <italic>Caenorhabditis elegans eat-2</italic> Mutants.</article-title>
            <source>Genetics</source>
            <year>2019</year>
            <month>May</month>
            <volume>212</volume>
            <issue>1</issue>
            <fpage>231</fpage>
            <page-range>231-243</page-range>
            <pub-id pub-id-type="pmid">30898771</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Perez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Aronsson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Alothmani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Winder</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Combination drug therapy against OAB normalizes micturition parameters and increases the release of nitric oxide during chemically induced cystitis.</article-title>
            <source>Pharmacol Res Perspect</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>e00564</fpage>
            <pub-id pub-id-type="pmid">32030913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albertson</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Chenoweth</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Pearson</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Murin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The pharmacological management of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS).</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>213</fpage>
            <page-range>213-231</page-range>
            <pub-id pub-id-type="pmid">31955671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hahn</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Stanford</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Goolsby Hunter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Essoi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Patient-Reported Burden of Illness in a Prevalent COPD Population Treated with Long-Acting Muscarinic Antagonist Monotherapy: A Claims-Linked Patient Survey Study.</article-title>
            <source>Pulm Ther</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>69</fpage>
            <page-range>69-80</page-range>
            <pub-id pub-id-type="pmid">32026428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Comparison of recovery profiles in patients with Parkinson's disease for 2 types of neuromuscular blockade reversal agent following deep brain stimulator implantation.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>98</volume>
            <issue>52</issue>
            <fpage>e18406</fpage>
            <pub-id pub-id-type="pmid">31876713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Russell</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Mohammadi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ligon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Latorre</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Hoang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Krull</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Eidam</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>DeMartino</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oliff</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Greenwood-Van Meerveld</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Enteric RET inhibition attenuates gastrointestinal secretion and motility via cholinergic signaling in rat colonic mucosal preparations.</article-title>
            <source>Neurogastroenterol Motil</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>31</volume>
            <issue>4</issue>
            <fpage>e13479</fpage>
            <pub-id pub-id-type="pmid">30311722</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathis</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Feldkaemper</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaeffel</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Studies on retinal mechanisms possibly related to myopia inhibition by atropine in the chicken.</article-title>
            <source>Graefes Arch Clin Exp Ophthalmol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>258</volume>
            <issue>2</issue>
            <fpage>319</fpage>
            <page-range>319-333</page-range>
            <pub-id pub-id-type="pmid">31879820</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McConaghy</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Fosselman</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Hyperhidrosis: Management Options.</article-title>
            <source>Am Fam Physician</source>
            <year>2018</year>
            <month>Jun</month>
            <day>01</day>
            <volume>97</volume>
            <issue>11</issue>
            <fpage>729</fpage>
            <page-range>729-734</page-range>
            <pub-id pub-id-type="pmid">30215934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tao</surname>
                <given-names>YX</given-names>
              </name>
              <name>
                <surname>Conn</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Chaperoning G protein-coupled receptors: from cell biology to therapeutics.</article-title>
            <source>Endocr Rev</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>35</volume>
            <issue>4</issue>
            <fpage>602</fpage>
            <page-range>602-47</page-range>
            <pub-id pub-id-type="pmid">24661201</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moss</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sachse</surname>
                <given-names>FB</given-names>
              </name>
              <name>
                <surname>Moreno-Galindo</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Navarro-Polanco</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Tristani-Firouzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Seemann</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Modeling effects of voltage dependent properties of the cardiac muscarinic receptor on human sinus node function.</article-title>
            <source>PLoS Comput Biol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>14</volume>
            <issue>10</issue>
            <fpage>e1006438</fpage>
            <pub-id pub-id-type="pmid">30303952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Urso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>D'Ovidio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Emala</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Bunnett</surname>
                <given-names>NW</given-names>
              </name>
              <name>
                <surname>Perez-Zoghbi</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Bile acids inhibit cholinergic constriction in proximal and peripheral airways from humans and rodents.</article-title>
            <source>Am J Physiol Lung Cell Mol Physiol</source>
            <year>2020</year>
            <month>Feb</month>
            <day>01</day>
            <volume>318</volume>
            <issue>2</issue>
            <fpage>L264</fpage>
            <page-range>L264-L275</page-range>
            <pub-id pub-id-type="pmid">31800261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ai</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>M<sub>3</sub> receptor modulates extracellular matrix synthesis via ERK1/2 signaling pathway in human bladder smooth muscle cells.</article-title>
            <source>J Cell Biochem</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>121</volume>
            <issue>11</issue>
            <fpage>4496</fpage>
            <page-range>4496-4504</page-range>
            <pub-id pub-id-type="pmid">32065420</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zuccolo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Laforenza</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Negri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Botta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Berra-Romani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Faris</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scarpellino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Forcaia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pellavio</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sancini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moccia</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Muscarinic M5 receptors trigger acetylcholine-induced Ca<sup>2+</sup> signals and nitric oxide release in human brain microvascular endothelial cells.</article-title>
            <source>J Cell Physiol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>234</volume>
            <issue>4</issue>
            <fpage>4540</fpage>
            <page-range>4540-4562</page-range>
            <pub-id pub-id-type="pmid">30191989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buels</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Fryer</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Muscarinic receptor antagonists: effects on pulmonary function.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2012</year>
            <issue>208</issue>
            <fpage>317</fpage>
            <page-range>317-41</page-range>
            <pub-id pub-id-type="pmid">22222705</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirshman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Lande</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Croxton</surname>
                <given-names>TL</given-names>
              </name>
            </person-group>
            <article-title>Role of M2 muscarinic receptors in airway smooth muscle contraction.</article-title>
            <source>Life Sci</source>
            <year>1999</year>
            <volume>64</volume>
            <issue>6-7</issue>
            <fpage>443</fpage>
            <page-range>443-8</page-range>
            <pub-id pub-id-type="pmid">10069508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamanishi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chapple</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Chess-Williams</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Which muscarinic receptor is important in the bladder?</article-title>
            <source>World J Urol</source>
            <year>2001</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>299</fpage>
            <page-range>299-306</page-range>
            <pub-id pub-id-type="pmid">11760777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abrams</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Andersson</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Muscarinic receptor antagonists for overactive bladder.</article-title>
            <source>BJU Int</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>100</volume>
            <issue>5</issue>
            <fpage>987</fpage>
            <page-range>987-1006</page-range>
            <pub-id pub-id-type="pmid">17922784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barathi</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>QS</given-names>
              </name>
              <name>
                <surname>Weon</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Seet</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Goh</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Vithana</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Beuerman</surname>
                <given-names>RW</given-names>
              </name>
            </person-group>
            <article-title>Muscarinic cholinergic receptor (M2) plays a crucial role in the development of myopia in mice.</article-title>
            <source>Dis Model Mech</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>1146</fpage>
            <page-range>1146-58</page-range>
            <pub-id pub-id-type="pmid">23649821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamelmann</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium.</article-title>
            <source>Biomed Res Int</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>7473690</fpage>
            <pub-id pub-id-type="pmid">30474042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stashak</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Brewer</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Management of hyperhidrosis.</article-title>
            <source>Clin Cosmet Investig Dermatol</source>
            <year>2014</year>
            <volume>7</volume>
            <fpage>285</fpage>
            <page-range>285-99</page-range>
            <pub-id pub-id-type="pmid">25378942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yarker</surname>
                <given-names>YE</given-names>
              </name>
              <name>
                <surname>Goa</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Fitton</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Oxybutynin. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability.</article-title>
            <source>Drugs Aging</source>
            <year>1995</year>
            <month>Mar</month>
            <volume>6</volume>
            <issue>3</issue>
            <fpage>243</fpage>
            <page-range>243-62</page-range>
            <pub-id pub-id-type="pmid">7620236</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perera</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Fischer</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dewenter</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vettel</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bork</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Conti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wess</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>El-Armouche</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hasenfu&#x000df;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nikolaev</surname>
                <given-names>VO</given-names>
              </name>
            </person-group>
            <article-title>Atropine augments cardiac contractility by inhibiting cAMP-specific phosphodiesterase type 4.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Nov</month>
            <day>09</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>15222</fpage>
            <pub-id pub-id-type="pmid">29123207</pub-id>
          </element-citation>
        </ref>
        <ref id="article-91323.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schittkowski</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Sturm</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>[Atropine for the Prevention of Progression in Myopia - Data, Side Effects, Practical Guidelines].</article-title>
            <source>Klin Monbl Augenheilkd</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>235</volume>
            <issue>4</issue>
            <fpage>385</fpage>
            <page-range>385-391</page-range>
            <pub-id pub-id-type="pmid">29270929</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
